CRISPR Therapeutics Gestion

Gestion contrôle des critères 3/4

Le PDG CRISPR Therapeutics est Sam Kulkarni, nommé en Dec2017, a un mandat de 6.92 ans. La rémunération annuelle totale est $ 12.32M, composée du salaire de 5.9% et des bonus 94.1%, y compris les actions et options de la société. détient directement 0.37% des actions de la société, d'une valeur de $ 17.13M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.1 ans et 5.4 ans.

Informations clés

Sam Kulkarni

Directeur général

US$12.3m

Rémunération totale

Pourcentage du salaire du PDG	5.9%
Durée du mandat du directeur général	6.9yrs
Propriété du PDG	0.4%
Durée moyenne d'occupation des postes de direction	5.1yrs
Durée moyenne du mandat des membres du conseil d'administration	5.4yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Sam Kulkarni a-t-elle évolué par rapport aux bénéfices de CRISPR Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$240m
Jun 30 2024	n/a	n/a	-US$266m
Mar 31 2024	n/a	n/a	-US$217m
Dec 31 2023	US$12m	US$725k	-US$154m
Sep 30 2023	n/a	n/a	-US$354m
Jun 30 2023	n/a	n/a	-US$416m
Mar 31 2023	n/a	n/a	-US$524m
Dec 31 2022	US$21m	US$700k	-US$650m
Sep 30 2022	n/a	n/a	-US$681m
Jun 30 2022	n/a	n/a	-US$633m
Mar 31 2022	n/a	n/a	US$312m
Dec 31 2021	US$17m	US$670k	US$378m
Sep 30 2021	n/a	n/a	US$412m
Jun 30 2021	n/a	n/a	US$447m
Mar 31 2021	n/a	n/a	-US$392m
Dec 31 2020	US$9m	US$625k	-US$349m
Sep 30 2020	n/a	n/a	-US$211m
Jun 30 2020	n/a	n/a	US$20m
Mar 31 2020	n/a	n/a	US$46m
Dec 31 2019	US$16m	US$550k	US$67m
Sep 30 2019	n/a	n/a	-US$11m
Jun 30 2019	n/a	n/a	-US$200m
Mar 31 2019	n/a	n/a	-US$185m
Dec 31 2018	US$10m	US$518k	-US$165m
Sep 30 2018	n/a	n/a	-US$117m
Jun 30 2018	n/a	n/a	-US$91m
Mar 31 2018	n/a	n/a	-US$75m
Dec 31 2017	US$7m	US$405k	-US$68m

Rémunération vs marché: La rémunération totale de Sam ($USD 12.32M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché UK ($USD 2.83M ).

Rémunération et revenus: La rémunération de Sam a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Sam Kulkarni (46 yo)

6.9yrs

Titularisation

US$12,322,196

Compensation

Dr. Samarth Kulkarni, Ph D, also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as Independent Director of Oruka Therapeutics, Inc since...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Samarth Kulkarni	CEO & Chairman	6.9yrs	US$12.32m	0.37% $ 17.1m
Raju Prasad	Chief Financial Officer	1.7yrs	US$5.91m	0.012% $ 548.8k
James Kasinger	General Counsel & Secretary	7.5yrs	US$3.51m	0.073% $ 3.4m
Shaun Foy	Founder	no data	pas de données	pas de données
Emmanuelle Charpentier	Co-Founder & Scientific Advisory Board Member	no data	pas de données	pas de données
Craig Mello	Scientific Founder & Advisory Board Member	no data	pas de données	pas de données
Chad Cowan	Scientific Founder	no data	pas de données	pas de données
Matthew Porteus	Scientific Founder & Advisory Board Member	no data	pas de données	pas de données
Daniel Anderson	Scientific Founder & Advisory Board Member	no data	pas de données	pas de données
Julianne Bruno	Chief Operating Officer	less than a year	pas de données	0.016% $ 759.0k
Stephen Kennedy	Head of Technical Operations	5.1yrs	pas de données	pas de données
Susan Kim	Vice President of Corporate Communications & Investor Relations	no data	pas de données	pas de données

5.1yrs

Durée moyenne de l'emploi

49yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de 0VRQ est chevronnée et expérimentée (5.1 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Samarth Kulkarni	CEO & Chairman	6.4yrs	US$12.32m	0.37% $ 17.1m
Emmanuelle Charpentier	Co-Founder & Scientific Advisory Board Member	no data	pas de données	pas de données
Craig Mello	Scientific Founder & Advisory Board Member	no data	pas de données	pas de données
Matthew Porteus	Scientific Founder & Advisory Board Member	no data	pas de données	pas de données
Daniel Anderson	Scientific Founder & Advisory Board Member	no data	pas de données	pas de données
Douglas Treco	Lead Independent Director	4.4yrs	US$552.56k	0.0023% $ 109.6k
Ali Behbahani	Independent Director	9.6yrs	US$545.06k	0.00032% $ 15.0k
Katherine High	Independent Director	5.4yrs	US$532.56k	0% $ 0
Simeon George	Independent Director	9.6yrs	US$542.56k	0% $ 0
Stephen Elledge	Member of Scientific Advisory Board	no data	pas de données	pas de données
John Greene	Independent Director	5.4yrs	US$555.06k	0% $ 0
H. Fleming	Independent Director	3.4yrs	US$536.24k	0% $ 0

5.4yrs

Durée moyenne de l'emploi

58yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 0VRQ sont considérés comme expérimentés (ancienneté moyenne 5.4 ans).

CRISPR Therapeutics Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

Insufficient new directors

Recent updates

Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023)

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023)

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach

Now 22% undervalued after recent price drop

New minor risk - Shareholder dilution

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

New minor risk - Shareholder dilution

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022)

New minor risk - Share price stability

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$2.40 loss in 2Q 2022)

Now 23% undervalued after recent price drop

Insufficient new directors

New minor risk - Shareholder dilution

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022)

Now 20% undervalued

Full year 2022 earnings released: US$8.36 loss per share (vs US$4.97 profit in FY 2021)

CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023

CRISPR Therapeutics AG Provides Update on Its Ongoing Phase 1 Carbon(Tm) Trial of Ctx110(R)

Third quarter 2022 earnings released: US$2.24 loss per share (vs US$1.67 loss in 3Q 2021)

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Second quarter 2022 earnings released: US$2.40 loss per share (vs US$10.01 profit in 2Q 2021)

Investor sentiment improved over the past week

CRISPR Therapeutics AG Elects Maria Fardis as Board Member

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CRISPR Therapeutics AG Announces the Appointment of Phuong Khanh Morrow as Chief Medical Officer, Effective May 23, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.51 loss in 1Q 2021)

Now 22% undervalued after recent price drop

CRISPR Therapeutics Proposes Appointment of Maria Fardis to the Board of Directors

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

Investor sentiment deteriorated over the past week

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell Malignancies

Third quarter 2021 earnings released: US$1.67 loss per share (vs US$1.32 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$10.01 (vs US$1.30 loss in 2Q 2020)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Presents New Data in 22 Patients with Greater Than 3 Months Follow-Up Post-Treatment with Investigational Crispr/Cas9 Gene-Editing Therapy

First quarter 2021 earnings released: US$1.51 loss per share (vs US$1.15 loss in 1Q 2020)

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen